Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Chemoradiation for Unresectable Stage III NSCLC
NCT04092283Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2020
- Primary completion
- Dec 2028
- Countries
- 2
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Apr 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04092283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04092283.